Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures
نویسندگان
چکیده
منابع مشابه
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study)
Background: Recombinant activated factor VII induces hemostasis in patients with coagulopathy disorders. AryoSeven™ as a safe Iranian Recombinant activated factor VII has been available on our market. This study was performed to establish the safety of AryoSeven on patients with coagulopathy disorder. Methods: This single-center, descriptive,...
متن کاملResults of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
BACKGROUND Traumatic coagulopathy contributes to early death by exsanguination and late death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a procoagulant that might limit bleeding and improve trauma outcomes. METHODS We performed a phase 3 randomized clinical trial evaluating efficacy and safety of rFVIIa as an adjunct to direct hemostasis in major trauma. We stud...
متن کاملEvaluating Blood Requests and Transfusion Practice in Major Surgical Procedures
Background: Red blood cell and other blood products play a crucial role in management of different disease processes, but in spite of implementation of crucial steps to improve the process of request for blood and blood consumption, there is still not enough information available regarding the proper practice in many medical centres. We aimed to evaluate the status of blood product requests and...
متن کاملRecombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.
OBJECTIVE Analysis of safety and efficacy of recombinant activated factor VII (rFVIIa) used as the last resort for refractory bleeding after cardiac surgery. DESIGN Retrospective cohort analysis and matched pairs analysis with historic controls were performed. In the rFVIIa group, which also received conventional hemostatic therapy, data were collected for a median of 14 hrs from admission to...
متن کاملComparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding
AIM OF THE STUDY A retrospective observational study to compare safety and efficacy of high and low doses of recombinant activated factor VIIa (rFVIIa) in severe postcardiac surgical bleeding. PATIENTS AND METHODS From 2004 to 2014, all patients who received rFVIIa for bleeding after cardiac surgery were included and arranged in two groups; Group 1: Low dose (40-50 mcg/kg) (n = 98) and Group ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Surgery
سال: 2008
ISSN: 0004-0010
DOI: 10.1001/archsurg.2007.66